Orchid Pharma Shares

USFDA releases a copy of the EIR to the establishment that was the subject of an FDA or FDA-contracted inspection when the agency determines the inspection to be closed.

Orchid Pharma gained as much as 4.70 per cent on Wednesday following the annoucement about a $800 million loan, that the drugmaker said will be used for "new growth opportunities".

The shares of Biocon surged today after the biotechnology company entered into an agreement with Quark Pharmaceuticals for development of a new range of therapeutics.

USFDA releases a copy of the EIR to the establishment that was the subject of an FDA or FDA-contracted inspection when the agency determines the inspection to be closed.

Orchid Pharma gained as much as 4.70 per cent on Wednesday following the annoucement about a $800 million loan, that the drugmaker said will be used for "new growth opportunities".

The shares of Biocon surged today after the biotechnology company entered into an agreement with Quark Pharmaceuticals for development of a new range of therapeutics.